Know your Antibodies level & its potential to fight COVID-19 infections with our SARS CoV-2 Spike Antibody & SARS CoV-2 Neutralizing Antibody Tests.

Type of Antibody tests

SARS CoV-2 Spike Antibody Test

Quantitative test to detect antibodies(IgG) which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell.

Who should be tested for SARS CoV- 2 Spike Antibody test?

  • Prior to vaccination – to check antibody levels
  • Recovering from COVID-19 infection – ideally 3 to 4 weeks after infection
  • After 2nd dose of vaccination - ideally 2 to 3 weeks after 2nd dose of vaccination
Offer Price ₹ 1,400 Book now

SARS CoV-2 Neutralizing Antibody Test

Quantitative FDA approved Test to detect circulating neutralizing Antibodies against SARS CoV that neutralize RBD-ACE interaction.

In this regard, assessing the level of neutralizing antibodies (NAbs) that block viral entry into cells could be a critical parameter in determining protection from SARS-CoV-2 and management of convalescent plasma therapies.

Who should be tested for SARS CoV- 2 Neutralizing Antibody test?

  • Patients with high spike Antibody titres
  • post vaccinated to check neutralizing Antibodies
  • Frequent Travelers- high neutralizing Ab confirms better immunity to fight SARS CoV-2
Offer Price ₹ 4,000 Book now

Note- A high neutralizing Ab confirms better immunity to fight SARS CoV-2

Specimen Type: Serum / Plasma

Advantages of Oncquest panels:

  • Individual Comprehensive Antibody panels
  • Quantitative results
  • Faster reporting
  • Interpretive reporting for determining seroconversion & accessing vaccine candidates

References:

  • a) SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus | Communications Biology (nature.com)
  • b) Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e278 (2020)